P039 Cross-resistance to clinical and agricultural azoles among Aspergillus fumigatus strains isolated from humans and environment in Italy

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PMObjectivesIn Italy, a prevalence of 16.9% of resistance to clinical azoles was observed among Aspergillus fumigatus isolates from an agricultural environment. This spread of azole-resistance is attributed to the widespread use of 14a-demethylase inhibitors (DMIs).The aims of the present study were to investigate: the DMIs resistance in Italian A. fumigatus strains of clinical and environmental origin, both susceptible and resistant to clinical azoles; the molecular mechanism of resistance in strains susceptible to clinical azoles but resistant to at least one of the tested DMIs; the in vitro DMI resistance induced by prolonged exposure to DMIs in susceptible clinical and environmental strains, and the molecular mechanism of resistance.MethodsA total of 54 A. fumigatus strains were selected: 23 susceptible to clinical azoles (CAS) and 31 resistant (CAR) with and without mutations in the CYP51A gene (TR34/L98H, F219I, G54R, G54E, D269Y, M220I, or F46Y/M172V/N248T/D255E/E427K). Antifungal susceptibility testing was performed for 8 DMIs (tebuconazole, epoxiconazole, difenoconazole, propiconazole, tetraconazole, flusilazole, fenbuconazole, and prochloraz) using broth microdilution method according to EUCAST and CLSI methods. Mutations in CYP51A, CYP51B, and HMG1 genes were investigated in CAS with DMI high MIC values. In vitro induction of resistance was performed using the 8 DMIs on 11 (6 clinical and 5 environmental) A. fumigatus strains susceptible both to clinical azoles and DMIs. A suspension of 106 conidia was inoculated on glucose-yeast extract-peptone agar plates containing different DMIs at different concentrations and incubated at 37°C for 72 h for six repeated passages.ResultsComparable results were obtained using EUCAST and CLSI methods.Resistance (MIC ≥16) to tetraconazole and fenbuconazole was observed in 100% of isolates, both CAR and CAS. On the contrary, a statistically significant difference in tebuconazole, epoxiconazole, difenoconazole, propiconazole, and flusilazole MICs between CAR strains and CAS strains was observed with higher geometric means (GM) in CAR (range 4.9-9.3 mg/L) than in CAS (1.5-2.7 mg/L) strains. Prochloraz showed the lowest GMs: 0.6 and 0.25 mg/L in CAR and CAS strains, respectively.A significant difference of the GMs for all the DMIs tested, except prochloraz, was observed between the isolates harboring a TR34/L98H or a M220I mutation (GM range 10.4-16 mg/L) and those with other CYP51A mutations (GM range 1-4.6 mg/L).In the CAS showing high DMI MICs, the absence of CYP51A mutations was confirmed, while a synonymous mutation P394P, was identified in CYP51B. No mutations in HMG1 gene were found.In the induction tests, the prolonged exposure to DMIs showed an induced phenotypic resistance of 100% (11/11 isolates) for epoxiconazole, of 72.7% (8/11) for propiconazole, of 54% (6/11) for tebuconazole and difenoconazole, and of 9.1% (1/11) for prochloraz.Molecular analysis to understand if the phenotypic resistance corresponds to induced mutations in CYP51A, CYP51B, and HMG1 genes is in progress.ConclusionsPreliminary results confirm cross-resistance between clinical azoles and DMIs, with MIC differences between CAR and CAS and between strains with different mutations in the CYP51A gene. Furthermore, the ability of DMIs to induce resistance in vitro was highlighted.